InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.42
(
0.33%
)
US TECH 100
19,114.00
(
-0.49%
)
Dow Jones
39,523.81
(
0.95%
)
Brent Oil
84.93
(
1.08%
)
Bitcoin
61,178.45
(
-3.14%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: None

Monday, 08/23/2010 1:41:44 PM

Monday, August 23, 2010 1:41:44 PM

Post# of 177
Credit to poster ghmm on biotech values MB for picking up on this



http://clinicaltrials.gov/ct2/show/NCT01185860





Roche is recruiting for their phase 1 study of ITMN-191 boosted with Ritonavir. Many of us weren't sure if Roche would move forward with this study. This can be looked at as a good news/bad news story.

Good news: Roche hasn't given up on ITMN-191 due to tox problems. This bodes well for the INFORM study to which VRUS' RG7128 is partnered.

Bad news: Adding Ritonavir brings a fourth drug into the mixture which includes SOC. It's disappointing that ITMN-191 needs boosting and its future, and the continuation of the INFORM study, are still in question.

“I am a big believer in giving it all away and have always said that the best financial planning ends with bouncing the check to the undertaker.”


Mike Bloomberg

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up